All Biomarkers

    p-Tau 181 / 217 (Plasma)

    Neurological
    Alzheimer's
    pg/mL

    Phosphorylated tau (p-Tau 181 and 217) is a blood biomarker highly specific to Alzheimer's disease pathology, reflecting the tau protein changes that accompany the disease. A longevity practice tracks these emerging markers because they correlate closely with amyloid burden and can flag risk early.

    What It Measures

    The concentration of tau protein phosphorylated at threonine-217 (and 181) in plasma. These phospho-epitopes rise specifically with Alzheimer's disease (AD) neuropathology — abnormal amyloid-beta processing and tau tangle formation — and p-tau217 in particular tracks closely with amyloid-PET and cerebrospinal-fluid status, making it the most discriminative blood-based marker of AD pathology currently available.

    Optimal vs. Lab Range

    Longevity Optimal
    Below the reporting laboratory's validated cutpoint (assay-specific).

    Target range for optimal health and longevity based on research.

    Standard Lab
    Assay-specific; no universal reference range. p-tau217 is the most discriminative epitope; the FDA-cleared Lumipulse pTau217/Abeta42 plasma ratio reports result categories against validated cutpoints.

    Population-based reference range from standard labs.

    Why It Matters

    Phosphorylated tau — especially p-tau217 — has rapidly become the most clinically useful blood marker of Alzheimer's disease pathology. In head-to-head studies, plasma p-tau217 assays distinguish AD from other neurodegenerative conditions with an area under the curve around 0.95, approaching the performance of cerebrospinal fluid and amyloid-PET. In May 2025 the U.S. FDA cleared the first blood test to aid AD diagnosis — the Lumipulse G pTau217/beta-amyloid 1-42 plasma ratio — for symptomatic adults aged 55 and older, marking a shift toward accessible, blood-based detection. For a preventive, longevity-oriented practice, p-tau217 offers an early, minimally invasive signal of AD-type pathology, potentially years before clinical dementia, supporting earlier risk discussion and modifiable risk-factor management. It is an aid to assessment, not a stand-alone diagnosis, and results are interpreted by a physician in clinical context.

    When Low

    Below the assay's cutpoint: low probability of Alzheimer's-type amyloid/tau pathology at the time of testing. Continue risk-factor optimization and periodic reassessment as appropriate.

    When Optimal

    Values below the validated cutpoint indicate a low likelihood of AD pathology. Because thresholds are assay-specific, interpret against the reporting laboratory's reference and the overall clinical picture.

    When High

    Above the cutpoint: higher likelihood of Alzheimer's-type pathology. This warrants clinical correlation and, where appropriate, neurology referral and confirmatory testing (CSF or amyloid-PET). A single elevated result is an aid to diagnosis, not a diagnosis.

    How to Optimize

    p-tau reflects underlying disease biology rather than a lever to be "pushed," but the shared modifiable drivers of cognitive aging are worth optimizing: a Mediterranean/MIND dietary pattern, at least 150 minutes per week of aerobic activity plus resistance training, high-quality sleep (treating sleep apnea where present), tight control of blood pressure, glucose and ApoB, hearing correction, smoking cessation, and sustained cognitive and social engagement. Where p-tau and companion markers indicate likely AD pathology, disease-specific therapies (including anti-amyloid treatment) are considered under neurology guidance. This content is educational and not a substitute for medical advice.

    Key Interventions & Linked Compounds

    Strong (9/10)

    Key Interventions

    MIND/Mediterranean diet
    aerobic + resistance exercise
    sleep optimization
    blood-pressure/glucose/ApoB control
    hearing correction
    anti-amyloid therapy under neurology guidance where indicated.

    Linked Compounds & Supplements

    DHA
    lithium (low dose)
    exercise.

    Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

    Ordering Notes

    Specimen

    Plasma immunoassay (e.g., Lumipulse pTau217/Abeta42 ratio)

    Patient prep

    No fasting required. Maintain usual diet and medications unless advised.

    Recommended cadence

    As clinically indicated (e.g., cognitive concern or elevated risk); repeat per physician guidance

    Reporting unit

    pg/mL

    Pre-analytic notes

    Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

    Available panels

    Plasma immunoassay (e.g., Lumipulse pTau217/Abeta42 ratio)
    High-sensitivity plasma assay (SIMOA)

    Recommended Follow-Up Actions

    1. 1

      Confirm the result is reliable

      Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift p-Tau 181 / 217 (Plasma).

    2. 2

      Compare against optimal, not just lab range

      Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.

    3. 3

      Pair with related markers

      Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.

    4. 4

      Discuss interventions with a clinician

      Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.

    5. 5

      Re-test on a defined cadence

      If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.

    Testing Information

    Recommended Frequency

    As clinically indicated (e.g., cognitive concern or elevated risk); repeat per physician guidance

    Fasting Requirement

    No fasting required

    Available Test Types

    Plasma immunoassay (e.g., Lumipulse pTau217/Abeta42 ratio)
    High-sensitivity plasma assay (SIMOA)
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation